hotspot -WSS

hotspot

author：leisure time 2025-09-30 15:15:22 - browse：65856

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Life science postdocs should get big pay hike, NIH panel says

WSS

3 trends to watch in health tech's hiring outlook for 2024

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

U.K. sequencing study surfaces new findings about tumor DNA

Feng Zhang CRISPR delivery startup lays off quarter of staff

Hospital chaplains balance Covid safety with patients’ spiritual needs

Gene therapy denied for Afghan refugee whose father aided U.S.

hotspot

hotspot

Gilead needs Arcellx more than ever

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA early review: GLP

Peter Hotez and the public health issue of online harassment

Stories you might have missed in 2023: health, science, medicine

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

GSK Flovent asthma inhalers replaced by authorized generics

What does generative AI mean for health care? We asked experts

The FDA must approve intranasal treatments for anaphylaxis

State Dept. review finds Biden bears some blame for Afghanistan failures

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

entertainment

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Study suggests new cause of Down syndrome: cells linked to aging

Stories you might have missed in 2023: health, science, medicine

Chronically ill young patients struggle to find fertility info

AdventHealth escalates lawsuit against insurance vendor Multiplan

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

knowledge

hotspot

knowledge

hotspot